MRC Clinical Trials Unit at UCL
Institute of Clinical Trials & Methodology
90 High Holborn 2nd Floor
London
WC1V 6LJ
Email: ICON6@ctu.mrc.ac.uk
Patients will be considered eligible for enrolment into this trial if they fulfil all of the inclusion criteria and none of the exclusion criteria, as defined below:
Patient inclusion criteria
Patient exclusion criteria
c - See trial assessments schedule for more details - table 2 in the protocol
d - The initial baseline scan should be done within 4 weeks prior to randomisation. However, a six week window would be considered after discussion with the CI
e - See Appendix 1 in the protocolf If the abnormal liver function tests are clearly attributable to liver metastases then serum transaminases (ALT and/or AST) values < 5x ULN are permitted
g - See Appendix 2 in the protocol
ICON6
MRC Clinical Trials Unit at UCL
Institute of Clinical Trials & Methodology
90 High Holborn 2nd Floor
London
WC1V 6LJ
Email: ICON6@ctu.mrc.ac.uk